Milestone Scientific's Epidural & Intra-Articular Subsidiary Announces Abstract Acceptance For Presentation At The Euroanaesthesia 2016 Congress

LIVINGSTON, NJ--(Marketwired - February 10, 2016) - Milestone Scientific Inc.'s (NYSE MKT: MLSS) Epidural & Intra-Articular (IA) Subsidiary today announced that its abstract entitled "A randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of the epidural space verification with the CompuFlo® Epidural Computer Controlled System (CompuFlo)," has been accepted for presentation at the prestigious Euroanaesthesia 2016 Congress taking place May 28-30, 2016 in London.

The abstract was authored by Dr. Douglas Dobecki, Diplomate of the American Board of Anesthesiology and a double-board certified anesthesiologist and interventional pain management expert from the San Diego Pain Institute. The abstract will be published in the supplement of the European Journal of Anaesthesiology that will coincide with the meeting.

Milestone's Epidural & Intra-Articular (IA) Subsidiary designed the study in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess the safety and effectiveness of the pressure sensing technology in identification of the epidural space.

Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "We are pleased to announce the acceptance of an abstract regarding our epidural instrument in yet another leading anesthesia journal, this time in Europe, and look forward to presenting the findings at the Euroanaesthesia 2016 Congress in London."

About Milestone Scientific Inc.

Milestone Scientific Inc. (NYSE MKT: MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website:

Back to news